Mutated EGFR-IN-1



Cat. No.:	HY-78869
CAS No.:	1421372-66-8
Molecular Formula:	$C_{25}H_{31}N_7O$
Molecular Weight:	445.56
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year

SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 75 mg/mL (168.33 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.2444 mL	11.2218 mL	22.4437 mL
	5 mM	0.4489 mL	2.2444 mL	4.4887 mL
	10 mM	0.2244 mL	1.1222 mL	2.2444 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Mutated EGFR-IN-1 (Osimertinib analog) is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant and T790M resistance mutant.IC50 value:Target: Mutated EGFR inhibitorMore information can be found in Patent WO 2013014448 A1.2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer.

IC_{50} & Target			
	$EGFR^{L858R}$	$EGFR^{Exon\ 19\ deletion/T790M}$	$EGFR^{T790M}$

REFERENCES

[1]. Patent WO 2013014448 A1. 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer .

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA